TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tenaya Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.38−0.00 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $82.16M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.4324 (−79.14%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $82.16M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.18
- Dividend yield
- –
- Free cash flow yield
- -64.01%
Fundamentals
- Net income
- -$103.12M
- EPS, diluted
- -$0.53
- Free cash flow
- -$52.59M
- Book value per share
- $0.32
- Diluted shares
- 218M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$105.86M
Net income
-$103.12M
EPS, diluted
-$0.53
Free cash flow
-$52.59M
Reported periodTrailing twelve months